Myleran (Busulfan)

Busulfan exerts its antineoplastic activity by forming covalent bonds with DNA, primarily at the N7 position of guanine. These alkylations create intra‑ and interstrand cross‑links that block DNA replication and transcription, leading to apoptosis of rapidly dividing hematopoietic cells. The drug’s effect is amplified in cells with limited DNA repair capacity.

The dosage of Myleran is individualized by the prescribing physician based on the patient’s disease, body surface area, liver function, and therapeutic drug monitoring results. Dosing regimens may involve single or divided oral administrations, and adjustments are made to achieve target plasma concentrations while minimizing toxicity. Patients should follow the prescriber’s specific instructions.

The safety of busulfan in pregnancy and lactation has not been established, and the drug is classified as contraindicated for use in pregnant women because of its potential to cause fetal harm. Breastfeeding is also discouraged, as busulfan can be excreted in milk and may affect the infant. Consultation with a specialist is essential before exposure.

To request Myleran, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any required cold‑chain handling—and assistance with import documentation.

The primary alternative to busulfan in conditioning regimens is cyclophosphamide, another alkylating agent. Busulfan offers a more predictable pharmacokinetic profile when therapeutic drug monitoring is applied, and it is associated with lower rates of certain organ toxicities such as cardiotoxicity. However, cyclophosphamide may be preferred when a broader immunosuppressive effect is needed. Choice depends on patient‑specific factors and institutional protocols.

Myleran tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack to protect from moisture and light. Do not refrigerate or freeze the product. Keep the medication out of reach of children and store it in a dry place away from direct sunlight to maintain stability throughout its shelf life.

Myleran is taken orally, usually with a glass of water, and may be administered with or without food depending on the prescriber’s guidance. The tablet should be swallowed whole and not crushed or chewed, unless the formulation specifically allows it. Dosing intervals and the total number of doses are determined by the treating physician and may be adjusted based on plasma level monitoring.

The most severe adverse events linked to busulfan include pulmonary fibrosis, hepatic veno‑occlusive disease, severe bone marrow suppression leading to life‑threatening infections or bleeding, and rare occurrences of secondary malignancies. Early detection through regular clinical and laboratory monitoring is critical, and any signs of respiratory distress, liver dysfunction, or unexplained cytopenias should prompt immediate medical evaluation.

Myleran is contraindicated in patients with known hypersensitivity to busulfan or any component of the formulation, those with severe hepatic impairment, and individuals with pre‑existing pulmonary fibrosis. Caution is also advised for patients with active infections, uncontrolled cardiovascular disease, or those who are pregnant or breastfeeding. The prescribing clinician must assess each patient’s medical history before initiating therapy.